News and Announcements
Why Dealing With Australia and UK Startups Attractive To Investors
- Published December 19, 2022 8:24AM UTC
- Publisher Rhori Stein
- Categories Capital Raising Tips
Based on data from Crunchbase, Australia has $145 per capita invested into startups annually. In the UK, that amount is 2.25x higher.
Having worked in both countries, some factors can explain this difference (tax incentives, cultural differences, risk appetites, etc.). But from an Australian perspective, I don’t feel that it’s down to a lack of quality deals. The ecosystem is growing rapidly, and the quality and diversity of companies I see are incredible.
For HNW/Angel investors, I think reduced investor competition presents the chance to get into deals that you wouldn’t get the opportunity to in other markets, which is a potentially excellent buying opportunity.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
